Skip to content

Adaptive Biotechnologies ADPT Deferred Tax Assets and Other Non-Current Assets

Deferred Tax Assets and Other Non-Current Assets at other companies

Guardant Health logo
Guardant HealthGH
Natera, Inc. logo
Natera, Inc.NTRA
Monte Rosa Therapeutics, Inc. logo
Monte Rosa Therapeutics, Inc.GLUE
GeneDx Holdings logo
GeneDx HoldingsWGS
Veracyte logo
VeracyteVCYT
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX

Other financials

Income statement

See full
Revenue$70.9M+35.1%
Gross profit$52.2M+47.1%
Operating income-$19.2M+35.1%
Net income-$20.0M+32.9%
EPS (diluted)-$0.13+35.0%

Balance sheet

See full
Cash & equivalents$77.6M+53.2%
Total debt$208.2M-5.6%
Total equity$216.3M+13.6%
Total assets$505.9M-1.0%

Cash flow

See full
Operating cash flow-$9.5M+66.5%
CapEx$796.0K-36.8%
Free cash flow-$10.3M+65.3%

Valuation

See full
Market cap$2.76B+93.6%
Enterprise value$2.89B+78.0%
P/S9.3×+1.8×

Profitability

See full
Gross margin75.3%+12.7pp
Operating margin-15.8%-7.0pp
Net margin-16.8%-7.3pp
FCF margin-10.5%-4.6pp

Returns & leverage

See full
Return on equity-24.4%-9.2pp
Debt / equity-0.2×
Current ratio3.4×+0.4×

Where this comes from

Reported directly by Adaptive Biotechnologies in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The official record: Adaptive Biotechnologies’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Adaptive Biotechnologies's deferred tax assets and other non-current assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Adaptive Biotechnologies's deferred tax assets and other non-current assets?
Adaptive Biotechnologies (ADPT) reported deferred tax assets and other non-current assets of $1.24M in Q1 2026.
How has Adaptive Biotechnologies's deferred tax assets and other non-current assets changed year-over-year?
Adaptive Biotechnologies's deferred tax assets and other non-current assets decreased by 34.4% year-over-year, from $1.89M to $1.24M.
What is the long-term trend for Adaptive Biotechnologies's deferred tax assets and other non-current assets?
Over 5 years (2020 to 2025), Adaptive Biotechnologies's deferred tax assets and other non-current assets has grown at a 15.1% compound annual growth rate (CAGR), from $598K to $1.21M.